Navigation Links
Aethlon Medical, Inc. - The Launch of a Clinical Program That Re-Thinks the Treatment of Viral Pathogens
Date:2/5/2015

SAN DIEGO, Feb. 5, 2015 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today published an article on The Chairman's Blog, written by the Company's Chairman and CEO, Jim Joyce.  TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In the article, entitled "The Launch of a Clinical Program That Re-Thinks the Treatment of Viral Pathogens," Mr. Joyce discusses the increasing incidence of viral epidemics as well as patient enrollment and the launch of the Company's first FDA approved study.  Read the full article from Mr. Joyce on TheChairmansBlog.com (http://www.thechairmansblog.com/aethlon-medical/james-joyce/launch-clinical-program-re-thinks-treatment-viral-pathogens).

About Aethlon Medical, Inc.

Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease, cancer and neurodegenerative disorders.  The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression.  Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties.  Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including Ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:

James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com 

David Zazoff
MDM Worldwide Solutions
646-403-3554

Logo - http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b

 


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Announces the Appointment of Chetan S. Shah, M.D. to its Board of Directors
2. Aethlon Medical to Present at Exosomes and Circulating Biomarkers 2013 Summit
3. Aethlon Medical Announces Launch of Exosome Sciences Subsidiary
4. Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
5. Aethlon Medical Announces the Appointment of Dr. Cicek Gercel-Taylor as Clinical Research Director of Exosome Sciences, Inc.
6. Aethlon Medical (AEMD) Note: Cancer Immunotherapy Article, Introduction to Dr. Douglas Taylor
7. Aethlon Medical to Present at SeeThruEquity Investor Conference
8. Aethlon Medical to Present at Biotech Showcase Investor Conference
9. Aethlon Medical and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform
10. Aethlon Medical Receives Notice of DARPA Contract Renewal
11. Aethlon Medical Announces Dengue Virus Treatment Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... WORTH, Texas (PRWEB) , ... July 17, 2019 ... ... deathcare management profession, recently tapped First American as its payment processor of record. ... and operators who use the Halcyon business management platform can now also accept ...
(Date:7/17/2019)... LAWRENCEVILLE, Ga. (PRWEB) , ... July 17, 2019 , ... ... 30044, is an established and trusted provider of complete dental care, including general and ... The practice is staffed with a large team of extensively trained dentists, Dr. Kell ...
(Date:7/17/2019)... ... July 17, 2019 , ... Triple W, an innovator ... for urinary incontinence, will be highlighted at the Japan - U.S. Innovation ... The Innovation Showcase recognizes startups with Japanese founders developing exciting technologies and highly ...
Breaking Medicine Technology:
(Date:7/11/2019)... ... July 11, 2019 , ... ... and educational resources with a range of features to further advance their mission ... pharmaceutical industry in manufacturing quality medicines for patients worldwide. The latest additions include ...
(Date:7/10/2019)... ... , ... Foggiare --the first and only U.S. company to offer Slim-Up ... technology. Developed by Sauna Italia , an Italian manufacturer of advanced aesthetic and ... over 180 locations in Europe and Asia. Slim-Up is scientifically proven to be effective ...
(Date:7/10/2019)... MALVERN, Pa. (PRWEB) , ... July 10, 2019 , ... ... (COA) as an official partner of the Oncology Clinical Pathways Congress, taking place October ... of the Journal of Clinical Pathways and focuses on the expansion of clinical pathways ...
(Date:7/9/2019)... ... July 10, 2019 , ... ... of Client Services Manager and will lead the growing team of client services ... First Healthcare Compliance and look forward to further developing new healthcare client relationships ...
(Date:7/9/2019)... ... July 10, 2019 , ... Women's Excellence is excited to offer laser vaginal rejuvenation. Laser vaginal ... as , painful sex , vaginal dryness and ... urinary urgency , vaginal pH imbalances , recurrent vaginal ...
Breaking Medicine News(10 mins):